Alto Neuroscience (NYSE:ANRO) Price Target Raised to $50.00

Alto Neuroscience (NYSE:ANRO) had its price objective boosted by HC Wainwright from $10.00 to $50.00 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

ANRO has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. Chardan Capital initiated coverage on shares of Alto Neuroscience in a report on Monday, September 29th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Robert W. Baird increased their target price on shares of Alto Neuroscience from $10.00 to $16.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Alto Neuroscience Trading Down 1.4%

ANRO opened at $11.03 on Friday. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $12.19. The company has a 50-day simple moving average of $5.03 and a 200 day simple moving average of $3.44. The company has a quick ratio of 18.43, a current ratio of 18.43 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $298.64 million, a price-to-earnings ratio of -4.61 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. Bank of Montreal Can bought a new stake in shares of Alto Neuroscience during the second quarter worth $25,000. Ground Swell Capital LLC bought a new position in Alto Neuroscience in the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC bought a new position in Alto Neuroscience in the 2nd quarter valued at approximately $33,000. AlphaCore Capital LLC raised its holdings in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after buying an additional 10,000 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Alto Neuroscience in the 1st quarter valued at approximately $52,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.